BACKGROUND: Daily controller medication use is recommended for children with persistent asthma to achieve asthma control. OBJECTIVE: To examine patterns of inhaled corticosteroid (ICS) use and asthma control in an observational study of children and adolescents with mild-to-moderate asthma (the Childhood Asthma Management Program Continuation Study). METHODS: We assessed patterns of ICS use during a 12-month period (consistent, intermittent, and none) and asthma control (well controlled vs poorly controlled). Multivariate logistic regression examined the association between pattern of ICS use and asthma control. RESULTS: Of 914 patients enrolled, 425 were recommended to continue receiving ICS therapy in the Childhood Asthma Management Program Continuation Study. Of these patients, 46% reported consistent ICS use and 20% reported no ICS use during year 1. By year 4, consistent ICS use decreased to 20%, whereas no ICS use increased to 57%; poorly controlled asthma was reported in 18% of encounters. In multivariate models controlling for age, sex, forced expiratory volume in 1 second, and asthma severity assessment, patients reporting consistent ICS use during a 12-month period were more likely to report poor asthma control (odds ratio, 1.6; 95% confidence interval, 1.2-2.1) compared with those reporting no ICS use. CONCLUSIONS: In this observational study of children and adolescents with mild-to-moderate asthma, most did not report continued use of ICS. Patients recommended to continue receiving ICS therapy and reporting consistent ICS use were less likely to report well-controlled asthma even after controlling for markers of asthma severity. Although residual confounding by severity cannot be ruled out, many children and adolescents may not achieve well-controlled asthma despite consistent use of ICS.
RCT Entities:
BACKGROUND: Daily controller medication use is recommended for children with persistent asthma to achieve asthma control. OBJECTIVE: To examine patterns of inhaled corticosteroid (ICS) use and asthma control in an observational study of children and adolescents with mild-to-moderate asthma (the Childhood Asthma Management Program Continuation Study). METHODS: We assessed patterns of ICS use during a 12-month period (consistent, intermittent, and none) and asthma control (well controlled vs poorly controlled). Multivariate logistic regression examined the association between pattern of ICS use and asthma control. RESULTS: Of 914 patients enrolled, 425 were recommended to continue receiving ICS therapy in the Childhood Asthma Management Program Continuation Study. Of these patients, 46% reported consistent ICS use and 20% reported no ICS use during year 1. By year 4, consistent ICS use decreased to 20%, whereas no ICS use increased to 57%; poorly controlled asthma was reported in 18% of encounters. In multivariate models controlling for age, sex, forced expiratory volume in 1 second, and asthma severity assessment, patients reporting consistent ICS use during a 12-month period were more likely to report poor asthma control (odds ratio, 1.6; 95% confidence interval, 1.2-2.1) compared with those reporting no ICS use. CONCLUSIONS: In this observational study of children and adolescents with mild-to-moderate asthma, most did not report continued use of ICS. Patients recommended to continue receiving ICS therapy and reporting consistent ICS use were less likely to report well-controlled asthma even after controlling for markers of asthma severity. Although residual confounding by severity cannot be ruled out, many children and adolescents may not achieve well-controlled asthma despite consistent use of ICS.
Authors: Scott T Weiss; Stephen L Lake; Eric S Silverman; Edwin K Silverman; Brent Richter; Jeffrey M Drazen; Kelan G Tantisira Journal: Proc Am Thorac Soc Date: 2004
Authors: Homer A Boushey; Christine A Sorkness; Tonya S King; Sean D Sullivan; John V Fahy; Stephen C Lazarus; Vernon M Chinchilli; Timothy J Craig; Emily A Dimango; Aaron Deykin; Joanne K Fagan; James E Fish; Jean G Ford; Monica Kraft; Robert F Lemanske; Frank T Leone; Richard J Martin; Elizabeth A Mauger; Gene R Pesola; Stephen P Peters; Nancy J Rollings; Stanley J Szefler; Michael E Wechsler; Elliot Israel Journal: N Engl J Med Date: 2005-04-14 Impact factor: 91.245
Authors: Michael Schatz; Robert S Zeiger; Alexandra Drane; Kathleen Harden; Aysel Cibildak; Jon E Oosterman; Mark Kosinski Journal: J Allergy Clin Immunol Date: 2006-12-27 Impact factor: 10.793
Authors: Stanley J Szefler; Brenda R Phillips; Fernando D Martinez; Vernon M Chinchilli; Robert F Lemanske; Robert C Strunk; Robert S Zeiger; Gary Larsen; Joseph D Spahn; Leonard B Bacharier; Gordon R Bloomberg; Theresa W Guilbert; Gregory Heldt; Wayne J Morgan; Mark H Moss; Christine A Sorkness; Lynn M Taussig Journal: J Allergy Clin Immunol Date: 2005-02 Impact factor: 10.793
Authors: Michael Schatz; David Mosen; Andrea J Apter; Robert S Zeiger; William M Vollmer; Thomas B Stibolt; Albin Leong; Michael S Johnson; Guillermo Mendoza; E Francis Cook Journal: J Allergy Clin Immunol Date: 2005-03 Impact factor: 10.793
Authors: Emmanuel Xystrakis; Siddharth Kusumakar; Sandra Boswell; Emma Peek; Zoë Urry; David F Richards; Tonye Adikibi; Carol Pridgeon; Margaret Dallman; Tuck-Kay Loke; Douglas S Robinson; Franck J Barrat; Anne O'Garra; Paul Lavender; Tak H Lee; Christopher Corrigan; Catherine M Hawrylowicz Journal: J Clin Invest Date: 2005-12-08 Impact factor: 14.808
Authors: Nicolas Roche; Jonathan D Campbell; Jerry A Krishnan; Guy Brusselle; Alison Chisholm; Leif Bjermer; Mike Thomas; Eric van Ganse; Maarten van den Berge; George Christoff; Jennifer Quint; Nikolaos G Papadopoulos; David Price Journal: Clin Transl Allergy Date: 2019-03-27 Impact factor: 5.871